Articles by Robert Langreth | Fortune

Skip to Content

NEW

A vastly improved search engine helps you find the latest on companies, business leaders, and news more easily.

SIGN IN

Health
Novavax shares soar after strong trial results for COVID-19 vaccine
By
Bloomberg
and
Robert Langreth
January 29, 2021
Health
Moderna raises 2021 vaccine output outlook to at least 600 million doses
By
Robert Langreth
and
Bloomberg
January 4, 2021
Health
Moderna vaccine cleared in U.S., boosting immunization effort
By
Anna Edney,
Robert Langreth,
and others
December 19, 2020
Health
Moderna to request clearance for COVID-19 vaccine in U.S. and EU
By
Bloomberg
and
Robert Langreth
November 30, 2020
Health
Pfizer, BioNTech plan filing as COVID trials show their vaccine is 95% effective
By
Robert Langreth
and
Bloomberg
November 18, 2020
Health
Moderna says its COVID-19 vaccine is 94.5% effective
By
Robert Langreth
and
Bloomberg
November 16, 2020
Health
Moderna shares soar as markets bet its COVID vaccine trial is on the same track as Pfizer’s
By
Robert Langreth
and
Bloomberg
November 12, 2020
Health
Pfizer and BioNTech take the lead after study shows their vaccine prevents 90% of infections
By
Robert Langreth,
Naomi Kresge,
and others
November 9, 2020
Health
Gilead shares jump on FDA approval of remdesivir
By
Robert Langreth
and
Bloomberg
October 23, 2020
International
AstraZeneca COVID-19 vaccine enters final-stage trial in the U.S.
By
Robert Langreth
and
Bloomberg
September 1, 2020
Health
Trump administration strikes another deal for a promising COVID-19 vaccine
By
Olivia Raimonde,
Robert Langreth,
and others
August 12, 2020
Health
Experts share a clearer timeline of when most Americans will get COVID-19 vaccine
By
Anna Edney,
Josh Wingrove,
and others
August 11, 2020
Health
Gilead to charge thousands for coronavirus treatment drug that critics say should cost $1
By
Robert Langreth
and
Bloomberg
June 29, 2020
Health
How accurate are the coronavirus tests used by the White House? A new report is raising questions
By
Michelle Fay Cortez,
Robert Langreth,
and others
May 13, 2020
Finance
Gilead shares tumble on reports that the Chinese trial of its coronavirus drug was not successful
By
Drew Armstrong,
Robert Langreth,
and others
April 23, 2020

1 - 15 of 20 results

1 - 15 of 20 results

© 2020 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell My Personal Information | Ad Choices
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.
Quotes delayed at least 15 minutes. Market data provided by Interactive Data. ETF and Mutual Fund data provided by Morningstar, Inc. Dow Jones Terms & Conditions: http://www.djindexes.com/mdsidx/html/tandc/indexestandcs.html.
S&P Index data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions.